Based on this hypothesis, a recently developed bromodomain inhibitor was proposed, targeting SWI/SNF complex to promote double-strand break and DNA repair [250], which demonstrates the feasibility for targeting SWI/SNF in cancer chemotherapy. This evidence concerns the gene SMARCA1 and cancer.